Neurogene Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. It has no approved products and has generated no product sales revenue. The December 2023 reverse merger and 1-for-4 reverse stock split affect comparisons with 2023.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $13.5 million | $10.3 million; up $3.3 million |
| General and administrative expense | $5.2 million | $2.8 million; up $2.5 million |
| Total operating expenses | $18.8 million | $13.0 million; up $5.7 million |
| Net loss | $16.9 million | $12.3 million |
| Net loss per share, basic and diluted | $1.00 | $28.28; not directly comparable due to the reverse merger and capital structure change |
| Cash, cash equivalents and short-term investments | $169.5 million at March 31 | $197.2 million at December 31, 2023 |
| Cash used in operating activities | $21.7 million | $13.6 million |
Interest income was $2.3 million, compared with $0.8 million a year earlier. Operating expenses increased as the company advanced NGN-401 and discovery work, and incurred higher public-company, personnel, and lease costs. There are no product margins to report. No material borrowings are reported; liabilities include $14.3 million of operating lease obligations and $0.1 million of finance lease obligations.
Cash flows included $30.0 million of proceeds from investment maturities and $7.1 million of financing outflows for offering and reverse-merger costs. Cash, cash equivalents and restricted cash ended the quarter at $150.5 million. The company reported $170.8 million of stockholders’ equity and an accumulated deficit of $204.1 million.
Business developments and outlook
- NGN-401, Rett syndrome: Phase 1/2 trial is enrolling. The protocol was amended to expand the low-dose cohort to eight patients and add an eight-patient high-dose cohort, allowing concurrent dose evaluation. The third patient in the low-dose cohort was dosed in March. The filing reports May 2024 data from the first three patients as showing a favorable early safety profile, with no treatment-emergent or procedure-related serious adverse events and no reported signs or symptoms indicative of overexpression-related toxicity. These early observations are limited and do not establish efficacy or longer-term safety.
- Management expects preliminary NGN-401 cohort data in Q4 2024 and an expanded dataset in the second half of 2025. The company expects to advance one discovery program into clinical development in 2025.
- NGN-101, CLN5 Batten disease: Enrollment in the first two cohorts is complete; a higher-dose cohort is enrolling. Interim data are expected in the second half of 2024. Management plans to request an FDA clinical/regulatory strategy meeting in the second half of 2024 to discuss a potential streamlined registration pathway.
- Management says current resources are expected to fund operations for at least 12 months after the financial statements’ issuance; elsewhere, the risk-factor discussion estimates runway into the second half of 2026. That longer estimate depends on operating-plan assumptions and may change.
- The company terminated its inherited at-the-market offering program in March 2024. It expects substantial ongoing losses and increasing R&D and administrative costs, and will need additional capital to develop and potentially commercialize its candidates.
Material changes, contingencies and risks
- Operating cash use rose to $21.7 million from $13.6 million. R&D expense increased primarily with NGN-401 trial costs, early discovery spending and personnel; G&A rose with public-company professional fees, lease costs, compensation and infrastructure.
- In April 2024, Neurogene licensed and assigned legacy Neoleukin assets to a third party. The agreement provides an approximately $0.75 million upfront payment, up to approximately $11 million in development, regulatory and commercialization milestones, and royalties. The upfront payment was received April 29; legacy CVR holders are entitled to 80% of net proceeds under the applicable terms. The company recorded a $0.3 million intellectual-property CVR liability at March 31 after eligible expense offsets; future milestone amounts were not then considered probable.
- The company recorded a $0.1 million impairment on idle equipment and continues to accrue costs to wind down the legacy NL-201 trial. It has no plans to continue the legacy Neoleukin de novo protein technology.
- Key risks include clinical and regulatory uncertainty, gene-therapy safety and durability, small rare-disease trial populations, manufacturing scale-up and supply constraints, reliance on academic and third-party collaborators, dependence on future financing, and the early-stage status of its intellectual-property portfolio. The company reports no material pending legal proceedings.
- Management concluded disclosure controls were effective at a reasonable assurance level and reported no material changes in internal control over financial reporting during the quarter. A material weakness related to a 2023 business-email-compromise incident was reported as remediated at year-end 2023; recurrence or other control weaknesses remain possible.
Important facts for investors to verify
- Whether NGN-401 and NGN-101 enrollment, safety findings and data timelines remain on track, and how much evidence supports efficacy and a registration path.
- The assumptions behind the stated cash runway, quarterly cash burn and timing or terms of any additional financing.
- Actual costs and milestones under the clinical, manufacturing and discovery plans, including the ability to scale in-house manufacturing.
- The terms, eligible offsets and eventual payments under the legacy asset and lease CVRs, including the third-party licensing agreement.
- Potential dilution from outstanding pre-funded warrants, options, restricted stock units and future equity financing; 4,063,361 pre-funded warrants were outstanding at March 31.